Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI).

Elexacaftor/Tezacaftor/Ivacaftor (ETI) is a CFTR modulator therapy approved for people with cystic fibrosis (pwCF) who have at least one phe508del mutation. However, its approval in the European Union (EU) for pwCF with non-phe508del mutations is lacking, because data on treatment response in this subgroup are scarce. This retrospective observational study evaluated six pwCF (ages 6 to 66) with responsive CFTR mutations (M1101K, R347P, 2789+5G>A, G551D) undergoing off-label ETI therapy.

Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study.

Allergen-specific immunotherapy (AIT) induces immune tolerance, showing the highest success rate (>95%) for insect venom while a much lower chance for pollen allergy. However, the molecular switches leading to successful durable tolerance restoration remain elusive. The primary outcome of this observational study is the comprehensive immunological cellular characterization during the AIT initiation phase, whereas the secondary outcomes are the serological and Th2-cell-type-specific transcriptomic analyses.

Unravelling spatiotemporal NO dynamics in an urbanized estuary system using natural abundance isotopes.

Estuaries are strong sources of NO to the atmosphere; yet we still lack insights into the impact of their biogeochemical dynamics on the emissions of this powerful greenhouse gas. Here, we investigated the spatiotemporal dynamics of the N cycle in an estuary with a focus on the emission mechanisms and pathways of NO. By coupling NO isotopocule analysis and substrate NO isotope analysis, we found that nutrient availability, oxygen level, salinity gradient and temperature variation were major drivers of the NO emissions from the Scheldt Estuary.